The estimated Net Worth of Brian D Schreiber is at least $6.31 mil dollars as of 22 May 2020. Brian Schreiber owns over 2,069 units of Windtree Therapeutics stock worth over $6,310 and over the last 6 years he sold WINT stock worth over $0. In addition, he makes $0 as Independent Director at Windtree Therapeutics.
Sign up
Brian Schreiber WINT stock SEC Form 4 insiders trading
Brian has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,069 units of WINT stock worth $15,000 on 22 May 2020.
The largest trade he's ever made was buying 2,069 units of Windtree Therapeutics stock on 22 May 2020 worth over $15,000. On average, Brian trades about 690 units every 0 days since 2019. As of 22 May 2020 he still owns at least 2,069 units of Windtree Therapeutics stock.
You can see the complete history of Brian Schreiber stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Schreiber biography
Dr. Brian D. Schreiber M.D. serves as Independent Director of the Company. Dr. Schreiber is a Board-Certified Nephrologist and Internist with extensive industry and clinical experience, specializing in rare diseases. Dr. Schreiber is currently the Chief Medical Officer for Cerium Pharmaceuticals, a company who leverages the basic drug discovery work performed by others and moves drug candidates through the clinical and regulatory development processes. Since 2015, Dr. Schreiber has also served as President and Managing Partner for Metabolism Disease Consultants, focusing on drug development, clinical trial design and in-licensing clinical guidance. Dr. Schreiber also served as Vice President of Medical Development at Relypsa and spent 14 years at Sigma-Tau Pharmaceuticals as consultant medical director and Vice President of its Medical Affairs Department. Dr. Schreiber’s clinical experience includes his role as Chief Medical Director of Dialysis Care Inc., a multi-center dialysis chain providing services in the Northeast and Central Wisconsin and Chairman of Nephrology at LaSalle Clinic, Affinity Medical System, serving as its first president until 2001. Dr. Schreiber has also continued his activities in academia as Assistant Clinical Professor of Medicine, Department of Medicine, Division of Nephrology, Medical College of Wisconsin since 2001, and has published numerous academic papers, given a variety of lectures, and ran various symposia.
How old is Brian Schreiber?
Brian Schreiber is 66, he's been the Independent Director of Windtree Therapeutics since 2018. There are 4 older and 10 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
What's Brian Schreiber's mailing address?
Brian's mailing address filed with the SEC is C/O WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Insiders trading at Windtree Therapeutics
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... y Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
What does Windtree Therapeutics do?
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
What does Windtree Therapeutics's logo look like?
Complete history of Brian Schreiber stock trades at Windtree Therapeutics
Windtree Therapeutics executives and stock owners
Windtree Therapeutics executives and other stock owners filed with the SEC include:
-
Craig Fraser,
President, Chief Executive Officer, Director -
Craig E. Fraser,
Pres, CEO & Director -
Steven Simonson,
Senior Vice President and Chief Medical Officer -
Eric L. Curtis M.B.A.,
Sr. VP & COO -
John P. Hamill,
Sr. VP, CFO & Corp. Sec. -
Mary Templeton,
Senior Vice President, General Counsel and Corporate Secretary -
James Huang,
Independent Chairman of the Board -
Brian Schreiber,
Independent Director -
Bruce Peacock,
Independent Director -
Joseph Mahady,
Independent Director -
John Leone,
Independent Director -
Daniel Geffken,
Independent Director -
Pratap Paruchuru,
Executive Director of Clinical Development -
Eric Curtis,
Chief Operating Officer, Senior Vice President -
John Hamill,
Chief Financial Officer, Senior Vice President -
Dr. Steven G. Simonson,
Sr. VP & Chief Medical Officer -
Diane Carman Esq.,
Sr. VP & Gen. Counsel -
Dr. Ronald L. Dundore,
Exec. Director of Regulatory Affairs & Quality -
Tracy Rarick,
Head of Operations & Program Management -
George Cox,
VP of Technical Operations -
Diane Carman,
SVP & General Counsel -
Leslie J. Williams,
Director -
Evan Loh,
Director -
Ii Investments Ltd Lph,
10% owner -
Pharmaceutical Holdings Ltd...,
10% owner -
John A Tattory,
SVP & CFO -
Mark Strobeck,
Director -
Capital Inc. Bioengine,
10% owner -
Laboratories, Inc. Center,
10% owner -
Robert A Scott,
Director